NEWS

  • We’re Hiring!

    Senior Manager/Associate Director of Research Programs MPN Research Foundation seeks an innovative, pragmatic, and collaborative Senior Manager or Associate Director (depending on experience) to manage our portfolio of research programs. The Foundation has a 20+year track record of impact on advancing disease knowledge and has influenced the evolving landscape of these rare blood cancers that… Read More »We’re Hiring!

    READ MORE

    MPN Awareness Day 2021

    Save the Date: Women & MPN

    Save the date for the 7th Annual Women & MPN conference, hosted in person in Washington, D.C. on September 24th, 2021 from 9:00 AM – 3:00 PM EST. MPN Research Foundation Executive Director Kapila Viges will be there to participate along with this impressive line-up of speakers:  Dr. Ruben Mesa, UT Health San Antonio  Dr. Ellen Ritchie, Weill Cornell Med  Dr. Michele Couri, University of Illinois  Dr. Laura… Read More »Save the Date: Women & MPN

    READ MORE

    Recordings Available from Texas Virtual MPN Workshop

    The recent Texas Virtual MPN Workshop: Second Annual Workshop and Meeting featured 30 speakers, including several whose research we funded, with participants from 77 countries. The presentations and panel discussions focused heavily on new and emerging clinical science on topics ranging from the very earliest stages of disease, including genetic predisposition to MPN, to strategies… Read More »Recordings Available from Texas Virtual MPN Workshop

    READ MORE

    NEWSLETTER ARCHIVE

    Click HERE to subscribe and receive future editions of our Under the Microscope electronic publication and/or our print newsletter, MPN Update, conveniently delivered to your email or home mailbox! 2022: Fall  |  Summer |  Spring 2021: Fall  |  Summer  |  Spring 2020: Fall  |  Summer  |  Spring 2019: Fall  |  Spring 2018: Fall  |  Spring 2017: Fall  |  Spring 2016: Fall  |  Spring 2015: Fall  |  Spring 2014: Fall  |  Spring 2013: Fall  |  Spring 2012: Fall  |  Spring 2011: Fall … Read More »NEWSLETTER ARCHIVE

    READ MORE

    Help Advance Myeloproliferative Neoplasms (MPN) Research from Home and Earn $100

    The MPN Research Foundation is reaching out to the MPN patient community to raise awareness about an opportunity for patients 18 years of age or older with Myeloproliferative Neoplasms (MPN). Patients who qualify can support research by providing a one-time blood donation from home. The blood sample will be collected by a mobile medical professional… Read More »Help Advance Myeloproliferative Neoplasms (MPN) Research from Home and Earn $100

    READ MORE

    ASCO RELEASES VIDEOS OF EXPERTS DISCUSSING MPDS

    December 2010 The American Society of Clinical Oncology (ASCO) recently released three videos of renowned MPD specialists discussing various topics related to MPDs. Drs. Ayalew Tefferi, William Vainchencker and James Vardiman contributed to the series. Click here to view videos

    READ MORE

    MPD CHAT ARCHIVES ASH ABSTRACTS

    December 2010 Online chat and support group MPD-Chat has listed all abstracts presented at the recent American Society of Hematology meeting that are relevant to MPD/MPN. Take a look at the abstract as well as the discussion boards. Thanks to MPD Chat for compiling this list!

    READ MORE

    2009 GRANT ANNOUNCEMENT

    The MPD Foundation is pleased to announce the recipients of our Research Alliance and New Investigator grants for 2009. This follows an extensive proposal review process conducted by our Scientific Advisory Board as well as additional MPD experts who gave generously of their time and expertise. Listed below are the grantee names, institutions and project… Read More »2009 GRANT ANNOUNCEMENT

    READ MORE

    A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

    This is an abstract that was presented at ASH’s annual meeting on Sunday, December 7, 2008: 4:45 PM 304-306-308 – South (Moscone Center) JAK2 V617F has been identified as a constitutive activating mutation in approximately half of patients with myelofibrosis (MF). MF, a myeloproliferative disorder comprised of primary myelofibrosis and the clinically indistinguishable entities of… Read More »A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

    READ MORE

    1 2 3 4 5 6 40
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?